Mink Therapeutics

Mink Therapeutics company information, Employees & Contact Information

We are a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease (GvHD). Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly versatile application for therapeutic development in cancer and immune diseases. We have leveraged our platform and manufacturing capabilities to develop a wholly owned pipeline for both native and engineered iNKT cells.

Company Details

Employees
31
Founded
-
Address
3 Forbes Rd, Lexington,massachusetts 02421,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Lexington, Massachusetts
Looking for a particular Mink Therapeutics employee's phone or email?

Mink Therapeutics Questions

News

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results - Yahoo Finance

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results Yahoo Finance

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA - GlobeNewswire

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA GlobeNewswire

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development - citybiz

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development citybiz

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors - Sahm

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors Sahm

Military Medicine Legend with 780 Publications: MiNK Therapeutics Adds Combat Care Pioneer to Board - Stock Titan

Military Medicine Legend with 780 Publications: MiNK Therapeutics Adds Combat Care Pioneer to Board Stock Titan

MiNK Therapeutics Extends Cash Runway and Advances Clinical Programs for GVHD and Gastric Cancer - Quiver Quantitative

MiNK Therapeutics Extends Cash Runway and Advances Clinical Programs for GVHD and Gastric Cancer Quiver Quantitative

MiNK Therapeutics Reports Clinical Advancements and Financial Update for Q1 2025, with Focus on iNKT Cell Therapies - Nasdaq

MiNK Therapeutics Reports Clinical Advancements and Financial Update for Q1 2025, with Focus on iNKT Cell Therapies Nasdaq

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - Yahoo Finance

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report Yahoo Finance

MiNK Therapeutics to Announce Q2 2025 Financial Results on August 14, 2025 | INKT Stock News - Quiver Quantitative

MiNK Therapeutics to Announce Q2 2025 Financial Results on August 14, 2025 | INKT Stock News Quiver Quantitative

Leading Pulmonary Disease Expert Dr. Hammond Joins MiNK to Advance Revolutionary iNKT Cell Therapy - Stock Titan

Leading Pulmonary Disease Expert Dr. Hammond Joins MiNK to Advance Revolutionary iNKT Cell Therapy Stock Titan

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting - Yahoo Finance

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting Yahoo Finance

MiNK Therapeutics Publishes Peer-Reviewed Article Highlighting Innovations in CAR-iNKT Cell Therapies for Solid Tumors - Quiver Quantitative

MiNK Therapeutics Publishes Peer-Reviewed Article Highlighting Innovations in CAR-iNKT Cell Therapies for Solid Tumors Quiver Quantitative

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development - GlobeNewswire

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development GlobeNewswire

MiNK Therapeutics Announces Frontiers in Immunology - GlobeNewswire

MiNK Therapeutics Announces Frontiers in Immunology GlobeNewswire

MiNK Therapeutics Announces Publication of Complete - GlobeNewswire

MiNK Therapeutics Announces Publication of Complete GlobeNewswire

MiNK Therapeutics Receives NIAID Grant to Advance Allo-iNKT Cell Therapy for Graft-Versus-Host Disease Treatment - Nasdaq

MiNK Therapeutics Receives NIAID Grant to Advance Allo-iNKT Cell Therapy for Graft-Versus-Host Disease Treatment Nasdaq

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients - GlobeNewswire

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients GlobeNewswire

MiNK Therapeutics Reports 2024 Financial Results and Highlights Clinical Advancements in iNKT Cell Therapies - Nasdaq

MiNK Therapeutics Reports 2024 Financial Results and Highlights Clinical Advancements in iNKT Cell Therapies Nasdaq

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress - GlobeNewswire

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress GlobeNewswire

Complete Remission Achieved in Treatment-Resistant Testicular Cancer with iNKT Cell Therapy | INKT Stock News - Stock Titan

Complete Remission Achieved in Treatment-Resistant Testicular Cancer with iNKT Cell Therapy | INKT Stock News Stock Titan

Revolutionary iNKT Cell Therapy Achieves 2-Year Complete Remission in Treatment-Resistant Cancer - Stock Titan

Revolutionary iNKT Cell Therapy Achieves 2-Year Complete Remission in Treatment-Resistant Cancer Stock Titan

MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewswire

MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements GlobeNewswire

MiNK Therapeutics to Present Updated Data from Phase 2 - GlobeNewswire

MiNK Therapeutics to Present Updated Data from Phase 2 GlobeNewswire

MiNK Therapeutics Presents Phase 2 Study of iNKT Cell Therapy for Advanced Gastroesophageal Cancers at ASCO GI Symposium - Quiver Quantitative

MiNK Therapeutics Presents Phase 2 Study of iNKT Cell Therapy for Advanced Gastroesophageal Cancers at ASCO GI Symposium Quiver Quantitative

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - GlobeNewswire

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI GlobeNewswire

MiNK Therapeutics Publishes Landmark Case of Complete Remission in Metastatic Testicular Cancer Following Treatment with AgenT-797 - Quiver Quantitative

MiNK Therapeutics Publishes Landmark Case of Complete Remission in Metastatic Testicular Cancer Following Treatment with AgenT-797 Quiver Quantitative

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors - Yahoo Finance

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors Yahoo Finance

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer - Investing News Network

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer Investing News Network

MiNK Therapeutics to Present Updated Clinical Data of - GlobeNewswire

MiNK Therapeutics to Present Updated Clinical Data of GlobeNewswire

MiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering - GlobeNewswire

MiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering GlobeNewswire

Top Mink Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant